Table 1.
Clinical and histopathological characteristics of study population grouped by tumor shrinkage pattern.
| Characteristics | Total patients (n = 199) | Type 1 shrinkage (n = 105) | Type 2 shrinkage (n = 94) | p-value |
|---|---|---|---|---|
| Age (mean ± SD) | 46.85 ± 10.13 | 47.95 ± 10.19 | 45.62 ± 9.97 | 0.105 |
| Menopausal status | 0.819 | |||
| Premenopausal | 116 (58.3%) |
62 (59.0%) |
54 (57.4%) |
|
| Postmenopausal | 83 (41.7%) |
43 (41.0%) |
40 (42.6%) |
|
| Histology | 0.152 | |||
| IDC | 191 (96.0%) |
103 (98.1%) |
88 (93.6%) |
|
| Other | 8 (4.0%) |
2 (1.9%) |
6 (6.4%) |
|
| Clinical stage | 0.133 | |||
| II | 98 (49.2%) |
57 (54.3%) |
41 (43.6%) |
|
| III | 101 (50.8%) |
48 (45.7%) |
53 (56.4%) |
|
| Clinical T stage | 0.139 | |||
| 1 | 5 (2.5%) |
3 (2.9%) |
2 (2.1%) |
|
| 2 | 127 (63.8%) |
73 (69.5%) |
54 (57.4%) |
|
| 3 | 50 (25.1%) |
24 (22.9%) |
26 (27.7%) |
|
| 4 | 17 (8.6%) |
5 (4.7%) |
12 (12.8%) |
|
| Clinical N stage | 0.829 | |||
| cN0 | 24 (12.1%) |
14 (13.3%) |
10 (10.6%) |
|
| cN1 | 105 (52.8%) |
54 (51.4%) |
51 (54.3%) |
|
| cN2 or cN3 | 70 (35.2%) |
37 (35.3%) |
33 (35.1%) |
|
| ER | 0.026 | |||
| Positive | 117 (58.8%) |
54 (51.4%) |
63 (67.0%) |
|
| Negative | 82 (41.2%) |
51 (48.6%) |
31 (33.0%) |
|
| PR | 0.019 | |||
| Positive | 101 (50.8%) |
45 (42.9%) |
56 (59.6%) |
|
| Negative | 98 (49.2%) |
60 (57.1%) |
38 (40.4%) |
|
| HER2 | 0.102 | |||
| Positive | 99 (49.7%) |
58 (55.2%) |
41 (43.6%) |
|
| Negative | 100 (50.3%) |
47 (44.8%) |
53 (56.4%) |
|
| Molecular subtype | 0.239 | |||
| HR+/HER2– | 66 (33.2%) |
30 (28.6%) |
36 (38.3%) |
|
| HER2+ | 99 (49.7%) |
58 (55.2%) |
41 (43.6%) |
|
| TN | 34 (17.1%) |
17 (16.2%) |
17 (18.1%) |
|
| Ki-67 | 0.048 | |||
| <30 | 83 (41.7%) |
37 (35.2%) |
46 (48.9%) |
|
| ≥30 | 116 (58.3%) |
68 (64.8%) |
48 (51.1%) |